Unity Biotechnology Inc Cash Flow Conversion Efficiency
Unity Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, Unity Biotechnology Inc (UBX) has a cash flow conversion efficiency ratio of 31.010x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($-205.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Unity Biotechnology Inc (2016–2024)
Cash flow conversion efficiency of Unity Biotechnology Inc from 2016 to 2024. This chart illustrates how Unity Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Unity Biotechnology Inc for real-time trading data and today's change.
Unity Biotechnology Inc Cash Flow Conversion Ratio Explained
Unity Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Unity Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unity Biotechnology Inc ranked by their cash flow conversion efficiency. Also see Unity Biotechnology Inc (UBX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mustang Bio Inc
NASDAQ:MBIO
|
-0.128x |
|
Innovotech Inc
V:IOT
|
-0.247x |
|
WEBUY GLOBAL LTD. Ordinary Shares
NASDAQ:WBUY
|
-0.215x |
|
Australian Silica Quartz Group Ltd
F:4B4
|
-0.076x |
|
Kridhan Infra Limited
NSE:KRIDHANINF
|
-0.004x |
|
Ordissimo
PA:ALORD
|
0.067x |
|
Videndum Plc
LSE:VID
|
-0.201x |
|
Cheetah Net Supply Chain Service Inc. Class A Common Stock
NASDAQ:CTNT
|
0.020x |
Annual Cash Flow Conversion Efficiency for Unity Biotechnology Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Unity Biotechnology Inc from 2016 to 2024. Review UBX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.49 Million | $-20.86 Million | -3.213x | -136.07% |
| 2023-12-31 | $28.40 Million | $-38.65 Million | -1.361x | -78.30% |
| 2022-12-31 | $66.85 Million | $-51.03 Million | -0.763x | -0.92% |
| 2021-12-31 | $59.57 Million | $-45.06 Million | -0.756x | +19.97% |
| 2020-12-31 | $82.88 Million | $-78.33 Million | -0.945x | -57.53% |
| 2019-12-31 | $120.71 Million | $-72.42 Million | -0.600x | -70.27% |
| 2018-12-31 | $160.69 Million | $-56.62 Million | -0.352x | +16.55% |
| 2017-12-31 | $90.84 Million | $-38.36 Million | -0.422x | -206.95% |
| 2016-12-31 | $-41.54 Million | $-16.40 Million | 0.395x | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more